Early Markers in Parkinson’s and Alzheimer’s Diseases PDF
Preview Early Markers in Parkinson’s and Alzheimer’s Diseases
NewVistas in Drug Research Vol. 1 P. Dostert, P. Riederer, M. Strolin Benedetti, and R. Roncucci (eds.) Early Markers in Parkinson's and Alzheimer's Diseases Springer-Verlag Wien New York Dr. Philippe Dostert Farmitalia Carlo Erba, Milan, Italy Prof. Dr. Peter Riederer Department of Psychiatry, University of Wiirzburg, Federal Republic of Germany Dr. Margherita Strolin Benedetti Farmitalia Carlo Erba, Milan, Italy Dr. Romeo Roncucci Farmitalia Carlo Erba, Milan, Italy This work ist subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically those of translation, reprinting, re-use of illustrations, broadcasting, reproduction by photocopying machines or similar means, and storage in data banks. © 1990 by Springer-Verlag/Wien Softcover reprint of the hardcover 1st edition 1990 Printed on acid-free paper Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in this book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. With 38 Figures (1 in color) Library of Congress Cataloging-in-Publication Data. Early markers in Parkinson's and Alzhei mer's diseases/Po Dostert (et al.) (eds.) p., cm. (New vistas in drug research; vol. 1.) Based on a conference which was organized by Erbamont and Carlo Erba Foundation. Includes index. ISBN-13:978-3-7091-9100-2 1. Parkinsonism-Diagnosis-Congresses. 2. Alz- heimer's disease-Diagnosis-Congresses. 3. Biochemical markers-Congresses. 1. Dostert, P. II. Erbamont Inc. III. Fondazione Carlo Erba. IV. Series. [DNLM: 1. Alzheimer's Disease- diagnosis-congresses. 2. Alzheimer's Disease--physiopathology-congresses. 3. Biological Markers--congresses. 4. Parkinson's Disease--diagnosis-congresses. 5. Parkinson's Disease-- physiopathology-congresses. WL 359 E12] RC382.E38 1990. 616.8'31075-dc20. 90-10419 ISSN 0938-9245 ISBN-13:978-3-7091-9100-2 e-JSBN-13:978-3-7091-9098-2 DOl: 10.1007/978-3-7091-9098-2 Welcome address I am really honored to open this first meeting of "New Vistas in Drug Research-Dialogues for the future" and to heartily welcome all the scientists, coming from 14 countries, who have accepted to offer here their contribution to exchange different experiences and to create new grounds for further scientific advances. The fact that Erbamont, along with the Carlo Erba Foundation, has organized this meeting is only a detail. We believe, as all the other phar maceutical companies based on a strong research and development, that we need to be more and more open to the scientific world, whose frontiers are getting broader day by day at an increasing speed. We have to run fast in this world and moments like these can give us the intellectual energy to run even faster. I am sure you will have a very productive and stimulating meeting. Thank you again for coming. P. Morrione Erbamont, President and Chief Executive Officer New Vistas today and tomorrow Dr. Montalcini, Dr. Guillemin, Dear Colleagues, the title of this series of meetings, "New Vistas in Drug Research" reflects the magic moment the pharmaceutical sciences are presently living, due to the tremendous progress of basic research, and of molecular biology in particular. Thanks to this progress, we are now sitting on the top of a hill from which we can look at the huge horizon with the various disciplines growing fast and cross-reacting with each other. Basic research is no longer isolated in an ivory tower but it's becoming the foundation on top of which new intelligent drugs can be built up. Based on the above, aim of these meetings is to stimulate dialog and constructive interaction between scientists with different background and of different affiliations. We are confident of the results of this cross-fertilization which could lead to new approaches for the topics that will be discussed in our New Vistas meetings. Today we are inaugurating the first of these meetings, whose title is "Early Markers in Parkinson's and Alzheimer's Dis eases". Already nowadays, but even more in the future, neurodegenerative disorders will constitute a major health problem, especially in developed countries. Despite advances in research, the management of these diseases is still hampered by the lack of a full understanding of their etiology and physio pathology. It is, however, our belief that with the increased knowledge of the real mechanisms involved in these pathological conditions, it seems now possible, within a reasonable period of time, to find more dedicated drug treatments for these terrible diseases. Parallely with this goal, it appears now possible to identify also reliable biological markers which could predict the onset of the disease at very early stages, possibly before lesions appear, giving doctors efficacious tools to check and monitor the presence of the disease or its evolution in association with new treatments. I sincerely hope that the discussions which will take place during this two-day meeting will contribute to the progress in this direction. Before leaving the floor to Dr. Montalcini, I wish to express my sincere thanks to all of you for having accepted to participate in this first New Vistas meeting. Thank you. R. Roncucci Erbamont, Research and Development, Vice President Acknowledgments The Editors are grateful to Patrizia Di Rosa for her dedicated assistance in the preparation of this volume. The Organizing Committee is deeply indebted to Patrizia Di Rosa, Gio vanna Garattini, Nadia La Spada, Luisa Stea and Rosanna Romaniello for their skilful contribution towards the success of the meeting. Contents Contributors . . XIII List of abbreviations . XIX Levi Montalcini, R.: Introduction EarlY markers in Parkinson's disease Przuntek, H.: Early markers in Parkinson's disease . 5 Agnoli, A., Stocchi, F., Carta, A.: Differential diagnosis of Parkinson's disease 13 Poewe, W.: The premorbid personality of patients with Parkinson's disease 23 Carvey, P. M., Klawans, H. L., Kao, L. C., Dahlstrom, A., McRae, A.: An antibody in the CSF of Parkinson's disease patients: summary of data and potential role as a diagnostic marker 31 Kraus, P. H., Klotz, P., Steinberg, R., Przuntek, H.: Contribution of motor performance tests to the early diagnosis of Parkinson's disease . 41 Liicking, C. H., Hufschmidt, A., Deuschl, G.: Electrophysiological methods in the early diagnosis of Parkinson's disease 49 Leenders, K. L.: Characterization of Parkinson's disease using positron emission tomography 59 Nagatsu, T., Mogi, M., Harada, M., Kojima, K.: Dopamine beta-hydroxylase and beta 2-microglobulin in cerebrospinal fluid: early markers in Parkinson's disease? . 71 Kienzl, E., Eichinger, K., Jellinger, K., Kuhn, W., Fuchs, G., Danielczyk, W., Wesemann, W., Riederer, P.: Urinary dopamine sulfate conjugates in Parkinson's disease . 79 Dostert, P., Strolin Benedetti, M., Dordain, G.: Salsolinol and the early de- tection of Parkinson's disease . 93 Olanow, C. W., Alberts, M., Djang, W., Stajich, J.: MR imaging of putamenal iron predicts response to dopaminergic therapy in parkinsonian patients 99 Youdim, M. B. H., Ben-Shachar, D.: The neurotoxic component in Parkinson's disease may involve iron-melanin interaction and lipid peroxidation in the substantia nigra . 111 Round table on Parkinson's disease . 123 EarlY markers in Alzheimer's disease Murphy, D. L., Sunderland, T.: The need for early markers in Alzheimer's disease 137 Amaducci, L., Lippi, A.: Descriptive and analytic epidemiology of Alzheimer's disease 147 XII Contents Gottfries, C. G.: Differential diagnosis of early Alzheimer's disease 155 Delabar, J. M., Blouin, J. L., Rahmani, Z., Creau-Goldberg, N., Chettouh, Z., Nicole, A., Bruel, A., de Blois, M. C., Sinet, P. M.: Down syndrome: a model for the study of Alzheimer's disease and aging 165 Heiss, W.-D., Szelies, B., Adams, R., Kessler, ]., Pawlik, G., Herholz, K.: PET scanning for the detection of Alzheimer's disease. . 181 Dierks, T., Maurer, K.: Reference-free evaluation of auditory evoked poten- tials-P300 in aging and dementia. .... 197 McBean, G.]., Horner, E. B., Couee, I., Phillips, J. P., O'Brien, M., Lee, T. C., Tipton, K. F.: Enzymes and glial cells in brain damage and neuro- degenerative diseases . 209 Riederer, P., Sofie, E., Moll, G., Freyberger, A., Wiehart, I., Gsell, W., Jellinger, K., Hebenstreit, G., Youdim, M. B. H.: Senile dementia of Alzheimer's type and Parkinson's disease: neurochemical overlaps and specific differences . . 221 Hoyer, S.: Changes in brain energy metabolism and the early detection of Alzheimer's disease. . 233 Nordberg, A.: Choline metabolism in Alzheimer's disease: hints as to possible markers . . . . . . . . . .. .... 245 McRae, A., Blennow, K., Wallin, A., Fredman, P., Gottfries, C. G., Dahl strom, A.: The presence of anti brain antibodies in the CSF of some Alzheimer disease patients: correlation with CSF parameters . 257 Oreland, L., Hiraga, Y., Jossan, S. S., Regland, B., Gottfries, C. G.: Increased monoamine oxidase activity and vitamin B-12 deficiency in dementia disorders 267 Round table on Alzheimer's disease 287 Guillemin, R.: Closing remarks 299 Subject index 303 Contributors * Adams, R. (181) Universitatsklinik fur Neurologie, Joseph-Stelzmann-Strasse 9, D-W-5000 Koln 41 (Lindenthal), Federal Republic of Germany. Agnoli, A. (13) I Clinic of Neurology, Department of Neurosciences, University "La Sapienza", Viale dell'Universid 30, 1-00185 Rome, Italy. Alberts, M. (99) Duke University, Department of Medicine, Service of Neurology, Durham, NC, U.S.A. Amaducci, L. (147, 287) Istituto delle Malattie Nervose e Mentali dell'Universid di Firenze, Viale Morgagni 85, 1-50134 Florence, Italy. Ben-Shachar, D. (111) Rappaport Research Institute, Department of Pharmacology, Faculty of Medicine, Technion, Haifa, Israel. Blennow, K. (257) Department of Psychiatry and Neurochemistry, St. Jorgens Hos pital, University of Goteborg, S-42203 Hisings Backa, Sweden. de Blois, M. C (165) H6pital Necker, Service de Cytogenetique, 149 rue de Sevres, F-75743 Paris, France. Blouin, J. L. (165) H6pital Necker, Laboratoire de Biochimie Genetique, 149 rue de Sevres, F-75743 Paris, France. Bruel, A. (165) H6pital Necker, Laboratoire de Biochimie Genetique, 149 rue de Sevres, F-75743 Paris, France. Brun, A. (287) Department of Pathology, Division of Neuropathology, University Hospital, S-221 85 Lund, Sweden. CaIne, D. B. (123) U.B.C Health Sciences Centre Hospital, Faculty of Medicine, 2211 Wesbrook Mall, Vancouver B.C, Canada V6TIW5. Caraceni, T. (123) Istituto Neurologico C Besta, Via Celoria 11, 1-20133 Milan, Italy. Carta, A. (13) I Clinic of Neurology, Department of Neurosciences, University "La Sapienza", Viale dell'Universita 30, 1-00185 Rome, Italy. Carvey, P. M. (31) Department of Neurological Sciences, Rush-Presbyterian St. Lukes Medical Center, 1753 West Harrison St., Chicago, IL 60616, U.S.A. Chettouh, Z. (165) H6pital Necker, Laboratoire de Biochimie Genetique, 149 rue de Sevres, F-75743 Paris, France. Couee, 1. (209) Department of Biochemistry, Trinity College, Dublin 2, Ireland. Creau-Goldberg, N. (165) H6pital Necker, INSERM U173, 149 rue de Sevres, F-75743 Paris, France. Dahlstrom, A. (31, 257) University of Goteborg, Institute of Neurobiology, P.O.B. 33031, S-40033 Goteborg, Sweden. Danielczyk, W. (79) LBI fUr Altersforschung, Neurologische Abteilung des Pflege heimes Lainz, Versorgungsheimplatz 1, A-1130 Wien, Austria. * Numbers in parentheses indicate the pages on which the authors' contributions begin.
The list of books you might like
